Do Blood Thinners Affect Antithrombin Deficiency Tests?
At a Glance
Yes, blood thinners like heparin, Eliquis, and Xarelto can cause inaccurate results on antithrombin deficiency tests. They can either falsely lower your score or make abnormal levels look perfectly normal. Testing is most accurate when medication is safely paused or genetic testing is used.
In this answer
3 sections
Yes, being on blood thinners when you are tested for antithrombin deficiency can absolutely cause inaccurate results. Medications like heparin and direct oral anticoagulants (DOACs) frequently interfere with the standard tests used to measure how well antithrombin works in your body [1][2]. Depending on the medication and the specific test, blood thinners can falsely lower your measured antithrombin score, or they can completely mask a true deficiency by making your levels look perfectly normal [3][4]. Because of this, tests for hereditary antithrombin deficiency are ideally performed when you are not actively taking these medications, or through specialized testing methods [5][6].
How Tests Measure Antithrombin (AT III)
Note: You may sometimes see antithrombin referred to as Antithrombin III or ATIII on older lab reports; these terms mean the exact same thing [7].
Doctors generally use two different types of tests to evaluate antithrombin:
- Functional assays (Activity assays): These tests measure how well your antithrombin is actually working to stop blood clotting. They are the standard first step for diagnosing a deficiency [5][8].
- Antigen assays: These tests simply measure the amount (or concentration) of antithrombin floating in your blood, regardless of whether it functions correctly [1][9].
Why Blood Thinners Interfere with Results
Blood thinners primarily interfere with functional assays, while antigen assays are generally unaffected [1][9]. The type of interference depends on the specific blood thinner you are taking [1]:
Heparin
Heparin and low-molecular-weight heparin (LMWH) work by binding to antithrombin. This interaction causes two main issues:
- False results in the lab: Because heparin boosts antithrombin’s activity, it can interfere with the chemical reactions in the test tube, leading to falsely elevated results if the test isn’t designed to neutralize it [1][10].
- Transient decreases in the body: Taking heparin actually causes your body to consume and clear out antithrombin faster than usual [11]. This means your antithrombin levels may temporarily drop while on the medication, making it look like you have a deficiency when you actually do not [12].
Direct Oral Anticoagulants (DOACs)
These medications severely interfere with standard functional tests, but the effect depends on the specific drug:
- Factor Xa Inhibitors (like rivaroxaban/Xarelto or apixaban/Eliquis) block clotting proteins the same way antithrombin does [2]. Because the test cannot tell the difference between the medication’s effect and your body’s natural antithrombin, it often produces a “false-negative” — meaning the test incorrectly shows normal antithrombin activity, masking an underlying hereditary deficiency [3][2].
- Direct Thrombin Inhibitors (like dabigatran/Pradaxa) interfere differently [13]. If the lab uses a thrombin-based assay, dabigatran will cause a “false-positive” by falsely decreasing the measured antithrombin activity [4][13].
Warfarin (Coumadin)
Unlike heparin and DOACs, Vitamin K antagonists like warfarin do not typically cause direct chemical interference with antithrombin functional assays [4]. However, long-term therapy or underlying conditions can still affect your overall clotting profile, so caution is always needed when interpreting results during active therapy [4].
The Impact of Acute Blood Clots
It is also important to know that having a recent, active blood clot (or being hospitalized for a major illness) forces your body to consume large amounts of antithrombin as it tries to break the clot down [14]. This acute consumption causes a temporary, physiological drop in antithrombin levels that can mimic a hereditary deficiency, even without the interference of medications [15]. Testing should ideally be avoided during the acute phase of a clot [5][16].
How to Get Accurate Results
Because misdiagnosing hereditary antithrombin deficiency can lead to improper long-term management or leave family members unaware of their risk, getting an accurate test is crucial [5][17]. Doctors use several strategies to ensure testing is reliable:
- Pausing Medication: Clinical guidelines generally recommend deferring antithrombin testing until your blood thinner has been discontinued for a safe and sufficient period [6][1]. For DOACs, this typically means pausing the medication for 48 to 72 hours, depending on your kidney function [18][19]. Never stop taking blood thinners without direct instructions from your doctor.
- Neutralization Reagents: If stopping your medication isn’t safe, specialized labs can use chemical neutralizers (like a product called DOAC-Stop) to remove the blood thinner’s effects from your blood sample before running the test [3][2].
- Genetic Testing (SERPINC1): If blood test results are borderline, confusing, or compromised by medications, doctors can use genetic sequencing to look directly at the SERPINC1 gene for mutations that cause antithrombin deficiency [20][21]. Since DNA is completely unaffected by blood thinners, genetic testing is a definitive way to confirm an inherited deficiency [22][20]. While highly accurate, genetic testing is not always the first-line choice because it is often more expensive and takes longer to get results [20].
Common questions in this guide
How do blood thinners like Eliquis affect antithrombin tests?
Can a recent blood clot cause low antithrombin levels?
Should I stop taking my blood thinner before an antithrombin test?
What is the most accurate way to test for antithrombin deficiency while on medication?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific type of antithrombin test did I have (functional or antigen), and could my blood thinner have affected the results?
- 2.Is it safe for me to briefly pause my blood thinners for retesting (and for how many days), or should we use a neutralization method like DOAC-Stop?
- 3.Could my low antithrombin levels be a temporary result of my recent blood clot rather than a genetic deficiency?
- 4.Given my history and test results, would genetic testing of the SERPINC1 gene be appropriate for me?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T, Flieder T, Fox V, et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2017; (51(4)):624-632 doi:10.1093/ejcts/ezw368.
PMID: 28043992 - 2
The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
Ząbczyk M, Natorska J, Kopytek M, et al.
Archives of pathology & laboratory medicine 2021; (145(1)):99-104 doi:10.5858/arpa.2020-0021-OA.
PMID: 33367661 - 3
Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals.
Jourdi G, Flaujac C, De Maistre E, et al.
Thrombosis and haemostasis 2025; doi:10.1055/a-2695-2674.
PMID: 41022132 - 4
Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms.
Schäfer ST, Otto AC, Acevedo AC, et al.
Thrombosis journal 2021; (19(1)):63 doi:10.1186/s12959-021-00313-7.
PMID: 34493301 - 5
Case report: A case of new mutation in SERPINC1 leading to thrombotic microangiopathy.
Li B, Zhang X, Lv H, et al.
Frontiers in genetics 2023; (14()):1278511 doi:10.3389/fgene.2023.1278511.
PMID: 37829283 - 6
2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management.
Tran HA, Merriman E, Baker R, et al.
Internal medicine journal 2025; (55(7)):1174-1183 doi:10.1111/imj.70103.
PMID: 40448969 - 7
Successful treatment for disseminated intravascular coagulation (DIC) corresponding to phenotype changes in a heat stroke patient.
Matsumoto H, Takeba J, Umakoshi K, et al.
Journal of intensive care 2019; (7()):2 doi:10.1186/s40560-019-0359-3.
PMID: 30675362 - 8
Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency.
Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, et al.
Thrombosis and haemostasis 2016; (116(1)):146-54 doi:10.1160/TH15-11-0871.
PMID: 27098529 - 9
Challenges to Laboratory Monitoring of Direct Oral Anticoagulants.
Qiao J, Tran MH
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024; (30()):10760296241241524 doi:10.1177/10760296241241524.
PMID: 38650302 - 10
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H, Rasmusson A, Söderblom L, et al.
International journal of laboratory hematology 2022; (44(1)):163-167 doi:10.1111/ijlh.13692.
PMID: 34523813 - 11
Trousseau syndrome: management of refractory VTE.
Zwicker JI
Hematology. American Society of Hematology. Education Program 2024; (2024(1)):253-258 doi:10.1182/hematology.2024000552.
PMID: 39644033 - 12
A narrative literature review on the clinical utility of activated partial thromboplastin time and anti-factor Xa activity assays in cancer patients with anticoagulant therapy.
Li HX, Song LH, Chen YH, et al.
Translational cancer research 2025; (14(10)):7438-7449 doi:10.21037/tcr-2025-1944.
PMID: 41234838 - 13
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M, Birschmann I, Peter A, et al.
Journal of the American Heart Association 2018; (7(19)):e009807 doi:10.1161/JAHA.118.009807.
PMID: 30371316 - 14
Antithrombin as Therapeutic Intervention against Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation: Lessons Learned from COVID-19-Associated Coagulopathy.
Wiedermann CJ
International journal of molecular sciences 2022; (23(20)) doi:10.3390/ijms232012474.
PMID: 36293332 - 15
Antithrombin Levels and Heparin Responsiveness during Venoarterial Extracorporeal Membrane Oxygenation: A Prospective Single-center Cohort Study.
Mansour A, Berahou M, Odot J, et al.
Anesthesiology 2024; (140(6)):1153-1164 doi:10.1097/ALN.0000000000004920.
PMID: 38271619 - 16
A review of laboratory considerations in thrombophilia testing.
Ong J, Bennett A
Pathology 2022; (54(7)):835-841 doi:10.1016/j.pathol.2022.09.001.
PMID: 36241557 - 17
Hereditary Antithrombin Deficiency Presenting with Cerebral Venous Thrombosis in Three Members of a Family.
Ashraf VV, Salam KA, Kizhedath R, Puthussery K
Neurology India 2023; (71(5)):984-986 doi:10.4103/0028-3886.388110.
PMID: 37929439 - 18
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Brückner L, Beyer-Westendorf J, Tiebel O, Pietsch J
Journal of thrombosis and thrombolysis 2022; (53(4)):777-787 doi:10.1007/s11239-021-02596-z.
PMID: 34762222 - 19
Viscoelastic monitoring of direct oral anticoagulants (DOAC).
Mora L, Pons-Pellicé L, Quintana-Díaz M
Blood transfusion = Trasfusione del sangue 2025; (23(1)):59-63 doi:10.2450/BloodTransfus.867.
PMID: 39621888 - 20
Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency.
Kim S, Lee WJ, Moon J, Jung KH
Frontiers in neurology 2022; (13()):841934 doi:10.3389/fneur.2022.841934.
PMID: 35720094 - 21
Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency.
de la Morena-Barrio B, Orlando C, Sanchis-Juan A, et al.
The Journal of molecular diagnostics : JMD 2022; (24(5)):462-475 doi:10.1016/j.jmoldx.2022.01.009.
PMID: 35218943 - 22
Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency.
Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, et al.
Thrombosis and haemostasis 2017; (117(6)):1040-1051 doi:10.1160/TH16-08-0635.
PMID: 28300866
This information explains how blood thinners impact antithrombin testing and is for educational purposes only. Always consult your hematologist or prescribing doctor before pausing or modifying any anticoagulant medications.
Get notified when new evidence is published on Hereditary thrombophilia due to congenital antithrombin deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.